By Investigative Staff
NEW YORK — As the calendar turns to December 2025, a poignant milestone marks the intersection of personal grief and public service. Ten years have passed since the death of Rochelle Shoretz, the visionary founder of Sharsheret, yet her legacy has never been more vibrant. In a year-end appeal that serves as both a retrospective and a call to action, her sons, Shlomo and Dovid Mirsky, are highlighting the organization’s meteoric rise from a dining room table gathering to an international movement that now supports over 275,000 individuals annually.
Main Facts: A Decade of Growth and a Lifetime of Impact
Sharsheret, the Hebrew word for "chain," was born out of a void in the healthcare landscape of the early 2000s. At the time, Rochelle Shoretz, a 28-year-old mother and former law clerk for U.S. Supreme Court Justice Ruth Bader Ginsburg, found herself facing a breast cancer diagnosis with few resources tailored to her specific cultural and demographic needs.
Today, the organization stands as the premier resource for Jewish women and families facing breast and ovarian cancer. The 2025 year-end campaign, spearheaded by Shoretz’s sons, aims to secure the financial future of the organization as it expands its reach. The Mirsky brothers, who were just three and five years old when their mother was first diagnosed, are now leading the charge to ensure that no family has to navigate the complexities of cancer in isolation.
The organization’s impact is staggering. From its humble beginnings in 2001, Sharsheret has evolved into a multi-faceted non-profit providing genetic counseling, mental health support, financial subsidies, and educational programming. Their reach now extends to all 50 U.S. states and several international territories, bridging the gap between medical treatment and the psychosocial needs of the patient and their family.
Chronology: From a Dining Room Table to a Global Chain
The history of Sharsheret is a timeline of resilience and rapid adaptation to the needs of a community in crisis.
2001: The Diagnosis and the Taboo
When Rochelle Shoretz was diagnosed in 2001, the "C-word" was still whispered in many corners of the Jewish community. There was a profound lack of guidance on how to manage a career, raise young children, and maintain religious observance while undergoing chemotherapy. Shoretz’s search for a peer led her to Lauryn Weiser, a fellow young Jewish mother who was slightly further along in her treatment. This connection became the blueprint for Sharsheret’s peer-support model.
2001–2010: Building the Foundation
What began as five women meeting in a dining room quickly gained momentum. Shoretz recognized that the Jewish community faced unique risks, specifically regarding the BRCA1 and BRCA2 genetic mutations, which are significantly more prevalent in those of Ashkenazi descent. Sharsheret began offering specialized resources that addressed these genetic predispositions alongside the cultural nuances of Jewish life.
2015: A Legacy Defined
Rochelle Shoretz passed away in 2015 at the age of 42. Her death was a significant blow to the community, but the infrastructure she built proved resilient. In the decade following her passing, the organization transitioned from a founder-led start-up to a professionally managed national institution.
2015–2025: Exponential Growth
Over the last ten years, Sharsheret has expanded its programming to include the "Busy Box" for children of parents with cancer, the "Best Face Forward" kit for those managing treatment side effects, and comprehensive genetic outreach. As of December 2025, the organization has reached a milestone of helping over 275,000 people annually, a testament to the enduring need for their services.
Supporting Data: The Statistics of Support
The scale of Sharsheret’s operations in 2025 reflects a data-driven approach to community health. The organization’s growth is underpinned by several key metrics that highlight the specific challenges faced by their constituents:
- Genetic Risk Factors: Research indicates that 1 in 40 individuals of Ashkenazi Jewish descent carries a BRCA gene mutation, compared to roughly 1 in 400 in the general population. This tenfold increase in risk necessitates the specialized genetic counseling and screening awareness programs that Sharsheret provides.
- Psychosocial Impact: According to Sharsheret’s internal data, children who receive support during a parent’s illness show higher levels of resilience. The "Busy Box" program, which the Mirsky brothers personally utilized as children, has distributed tens of thousands of kits containing age-appropriate resources to help children process their parent’s diagnosis.
- Community Outreach: The organization now partners with over 500 synagogues, Jewish Community Centers (JCCs), and campus Hillels across the United States. This network ensures that the "chain" of support is accessible at the local level.
- The 275,000 Benchmark: The current reach of 275,000 individuals per year includes not just patients, but caregivers, family members, and healthcare professionals who utilize Sharsheret’s educational webinars and clinical resources.
Official Responses: Voices from the Next Generation
In their year-end appeal, Shlomo and Dovid Mirsky provided a rare personal glimpse into the private life of a public figure. Their statement serves as an official endorsement of the organization’s continued relevance.
"Mom missed so many milestones—from graduations to grandchildren to Sharsheret reaching incredible heights," the brothers stated. "Despite Mom’s passing, Sharsheret has continued to grow and develop to help so many people and families who desperately need it. We know that thanks to your generosity, Mom is looking down with pride as we build a healthier and brighter future for the next generation."
Health experts and communal leaders have also weighed in on the organization’s 2025 milestone. Dr. Miriam Levinson, a clinical oncologist specializing in hereditary cancers, noted, "Sharsheret does what a hospital cannot. They provide the ‘life’ support—the cultural, emotional, and familial glue that holds a patient together when their world is upended by a diagnosis. Rochelle Shoretz’s vision changed the standard of care for Jewish women globally."
Implications: The Future of Specialized Cancer Care
The success of Sharsheret carries significant implications for the future of healthcare and non-profit management. It serves as a primary case study in the "niche-specialization" model of support, proving that addressing the specific cultural and religious needs of a group can lead to better health outcomes and higher engagement.
1. Breaking the Taboo of Genetic Testing
One of the most profound implications of Sharsheret’s work is the normalization of genetic testing within the Jewish community. By framing BRCA testing as a proactive health measure rather than a "death sentence" or a source of stigma, the organization has likely saved thousands of lives through early detection and preventative measures.
2. The Evolution of Peer Support
The "Sharsheret model" of peer-to-peer matching has been emulated by various other disease-specific organizations. The idea that a patient needs more than just a doctor—that they need a "mentor" who has walked the same path—has become a cornerstone of modern psychosocial oncology.
3. Continuity of Mission
The 2025 appeal highlights the challenge of "founder transition" in the non-profit sector. Many organizations falter after the loss of a charismatic founder. Sharsheret’s ability to thrive and decuple its impact in the ten years since Shoretz’s death suggests a robust organizational structure and a mission that resonates deeply with its donor base.
4. A Call to Action for 2026 and Beyond
As the Mirsky brothers look toward the future, the 2025 year-end campaign is not just about maintenance, but about evolution. Plans for the coming year include expanded digital platforms to reach younger demographics and increased advocacy for federal funding for hereditary cancer research.
Conclusion: A Brighter Future
The story of Sharsheret is a testament to the power of a single idea transformed into a collective mission. As Shlomo and Dovid Mirsky noted in their address to the community, the organization remains a "chain" that connects past loss to future hope.
For the thousands of families currently navigating a diagnosis, the legacy of Rochelle Shoretz is not found in a plaque or a building, but in the "Busy Box" a child opens, the phone call a worried husband makes to a counselor, and the genetic test that allows a young woman to take control of her destiny.
As the 2025 year-end campaign concludes, the message from the Mirsky family is clear: the work is far from over. In the spirit of Chanukah, the "Festival of Lights," Sharsheret continues to provide a beacon for those in their darkest hours, ensuring that the chain remains unbroken for generations to come.
For more information on how to support Sharsheret’s mission or to access their resources, visit link.Sharsheret.org/EOY.
About the Author
